Total Payments
$98,333
2024 Payments
$3,840
Companies
11
Transactions
55
Medicare Patients
357
Medicare Billing
$55,346
Payment Breakdown by Category
Consulting$75,636 (76.9%)
Research$20,079 (20.4%)
Travel$1,307 (1.3%)
Food & Beverage$869.21 (0.9%)
Other$442.00 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $75,636 | 15 | 76.9% |
| Unspecified | $20,079 | 4 | 20.4% |
| Travel and Lodging | $1,307 | 5 | 1.3% |
| Food and Beverage | $869.21 | 30 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $442.00 | 1 | 0.4% |
Payments by Type
General
$78,254
51 transactions
Research
$20,079
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $60,534 | 28 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $19,165 | 6 | $0 (2020) |
| Cepheid | $4,551 | 7 | $0 (2024) |
| F. Hoffmann-La Roche AG | $4,415 | 3 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $3,931 | 3 | $0 (2024) |
| AstraZeneca UK Limited | $2,420 | 1 | $0 (2020) |
| JAZZ PHARMACEUTICALS INC. | $1,610 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $1,125 | 1 | $0 (2020) |
| Puma Biotechnology, Inc. | $500.00 | 1 | $0 (2019) |
| Daiichi Sankyo Inc. | $62.51 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,840 | 4 | AstraZeneca Pharmaceuticals LP ($2,118) |
| 2023 | $51,700 | 2 | Eli Lilly and Company ($51,700) |
| 2022 | $3,955 | 1 | F. Hoffmann-La Roche AG ($3,955) |
| 2021 | $3,337 | 4 | AstraZeneca Pharmaceuticals LP ($1,813) |
| 2020 | $24,004 | 28 | Novartis Pharmaceuticals Corporation ($13,125) |
| 2019 | $5,701 | 8 | Novartis Pharmaceuticals Corporation ($3,042) |
| 2018 | $4,572 | 5 | Cepheid ($2,337) |
| 2017 | $1,223 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($764.00) |
All Payment Transactions
55 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $2,117.50 | General |
| Category: Oncology | ||||||
| 07/26/2024 | JAZZ PHARMACEUTICALS INC. | — | Consulting Fee | Cash or cash equivalent | $1,610.00 | General |
| 04/16/2024 | Cepheid | GeneXpert (Device) | Food and Beverage | In-kind items and services | $93.12 | General |
| Category: Devices | ||||||
| 02/28/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/31/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $51,000.00 | General |
| 07/25/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 03/31/2022 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $3,955.20 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER • Category: BioOncology | ||||||
| 11/17/2021 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: Iron Deficiency Anemia | ||||||
| 09/29/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 07/08/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $907.50 | General |
| 03/30/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $905.50 | General |
| 10/08/2020 | AstraZeneca UK Limited | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,420.00 | General |
| Category: Oncology | ||||||
| 09/11/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 08/27/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 03/09/2020 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $80.00 | General |
| 03/09/2020 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $23.92 | General |
| 03/09/2020 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $3.19 | General |
| 01/31/2020 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | In-kind items and services | $13,125.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT • Category: ONCOLOGY | ||||||
| 01/28/2020 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 01/17/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $265.00 | General |
| 01/17/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $92.59 | General |
| 01/17/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $41.65 | General |
| 01/17/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $23.15 | General |
| 01/17/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $22.22 | General |
| 01/17/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $18.52 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $13,125 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER | F. Hoffmann-La Roche AG | $3,955 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,998 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 309 | 611 | $175,060 | $47,332 |
| 2022 | 3 | 48 | 86 | $26,273 | $8,015 |
Total Patients
357
Total Services
697
Medicare Billing
$55,346
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88377 | Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | Office | 2023 | 103 | 186 | $63,486 | $26,519 | 41.8% |
| 88360 | Microscopic genetic analysis of tumor, manual | Office | 2023 | 93 | 252 | $58,024 | $10,688 | 18.4% |
| 88323 | Surgical pathology consultation and report on referred material requiring preparation of slides | Office | 2023 | 113 | 173 | $53,550 | $10,125 | 18.9% |
| 88377 | Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure | Office | 2022 | 16 | 30 | $11,208 | $5,185 | 46.3% |
| 88323 | Surgical pathology consultation and report on referred material requiring preparation of slides | Office | 2022 | 18 | 27 | $8,466 | $1,573 | 18.6% |
| 88360 | Microscopic genetic analysis of tumor, manual | Office | 2022 | 14 | 29 | $6,599 | $1,257 | 19.0% |
About Dr. Michael Press, MD
Dr. Michael Press, MD is a Anatomic Pathology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356380174.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Press, MD has received a total of $98,333 in payments from pharmaceutical and medical device companies, with $3,840 received in 2024. These payments were reported across 55 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($75,636).
As a Medicare-enrolled provider, Press has provided services to 357 Medicare beneficiaries, totaling 697 services with total Medicare billing of $55,346. Data is available for 2 years (2022–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Anatomic Pathology
- Location Los Angeles, CA
- Active Since 06/06/2006
- Last Updated 11/27/2023
- Taxonomy Code 207ZP0101X
- Entity Type Individual
- NPI Number 1356380174
Products in Payments
- PIQRAY (Drug) $15,359
- Kadcyla (Biological) $4,397
- KYMRIAH (Biological) $2,914
- LYNPARZA (Drug) $2,420
- ENHERTU (Biological) $2,118
- BYL719 (Drug) $764.00
- Nerlynx (Drug) $500.00
- KISQALI (Drug) $127.54
- GENEXPERT (Device) $120.81
- GeneXpert (Device) $93.12
- INJECTAFER (Drug) $62.51
- KRYSTEXXA (Biological) $19.82
- Herceptin (Biological) $17.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology Doctors in Los Angeles
Peter Tontonoz, Md, MD
Anatomic Pathology — Payments: $13.6M
Anatomic Pathology $13.6M
Sheeja Pullarkat, Md, MD
Anatomic Pathology — Payments: $213,828
Anatomic Pathology $213,828
Anthony Sisk, Do, DO
Anatomic Pathology — Payments: $82,608
Anatomic Pathology $82,608
Scott Nelson, Md, MD
Anatomic Pathology — Payments: $80,500
Anatomic Pathology $80,500
Dinesh Rao, Md, MD
Anatomic Pathology — Payments: $51,417
Anatomic Pathology $51,417
Hanlin Wang, Md, MD
Anatomic Pathology — Payments: $20,198
Anatomic Pathology $20,198